Production (Stage)
Collegium Pharmaceutical, Inc.
COLL
$29.61
$0.431.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 664.28M | 631.45M | 599.25M | 576.65M | 566.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 664.28M | 631.45M | 599.25M | 576.65M | 566.92M |
| Cost of Revenue | 86.07M | 83.53M | 79.91M | 79.39M | 78.94M |
| Gross Profit | 578.22M | 547.92M | 519.33M | 497.26M | 487.98M |
| SG&A Expenses | 220.48M | 186.03M | 160.33M | 153.56M | 148.42M |
| Depreciation & Amortization | 186.26M | 165.30M | 144.35M | 139.86M | 142.81M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 492.80M | 434.87M | 384.59M | 372.81M | 370.17M |
| Operating Income | 171.48M | 196.58M | 214.66M | 203.84M | 196.75M |
| Income Before Tax | 65.07M | 98.57M | 128.01M | 141.21M | 129.91M |
| Income Tax Expenses | 21.17M | 29.38M | 39.42M | 41.32M | 36.62M |
| Earnings from Continuing Operations | 43.89 | 69.19 | 88.59 | 99.89 | 93.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.89M | 69.19M | 88.59M | 99.89M | 93.29M |
| EBIT | 171.48M | 196.58M | 214.66M | 203.84M | 196.75M |
| EBITDA | 361.77M | 365.74M | 362.77M | 347.36M | 343.16M |
| EPS Basic | 1.36 | 2.14 | 2.74 | 3.06 | 2.83 |
| Normalized Basic EPS | 2.05 | 2.64 | 3.10 | 2.85 | 2.56 |
| EPS Diluted | 1.21 | 1.85 | 2.42 | 2.68 | 2.50 |
| Normalized Diluted EPS | 1.66 | 2.11 | 2.46 | 2.25 | 2.02 |
| Average Basic Shares Outstanding | 128.56M | 129.10M | 129.32M | 130.81M | 132.99M |
| Average Diluted Shares Outstanding | 153.50M | 162.10M | 163.27M | 165.16M | 167.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |